31 – 40 of 110
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
(
- Contribution to journal › Article
- 2015
-
Mark
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
(
- Contribution to journal › Article
-
Mark
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
(
- Contribution to journal › Article
-
Mark
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
(
- Contribution to journal › Article
-
Mark
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
(
- Contribution to journal › Article
-
Mark
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article
- 2014
-
Mark
Burchnall-Chaundy Theory for Ore Extensions
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
A note on "A combinatorial proof of associativity of Ore extensions"
(
- Contribution to journal › Article
-
Mark
Algebraic Properties of Ore Extensions and Their Commutative Subrings
2014)(
- Thesis › Doctoral thesis (compilation)